CCL2 and celiac disease: Among the pediatric studies, MCP-1 was evaluated only in Spanish children with celiac disease (n = 53) and healthy controls (n = 32) by comparing celiac participants with <50% vs. ≥50% of energy from UPF (plus controls) (Table 2) [48].